Creative Commons source reading · Epilepsy and seizure classification
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers.
Fei Tang; Anika M S Hartz; Björn Bauer
Originally published in Frontiers in neurology · 2017-07-06
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Epilepsy is a common neurological disorder that affects over 70 million people worldwide. Despite the recent introduction of new antiseizure drugs (ASDs), about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Early identification of patients who will become refractory to ASDs could help direct such patients to appropriate non-pharmacological treatment, but the complexity in the temporal patterns of epilepsy could make such identification difficult. The target hypothesis and transporter hypothesis are the most cited theories trying to explain refractory epilepsy, but neither theory alone fully explains the neurobiological basis of pharmacoresistance. This review summarizes evidence for and against several major theories, including the pharmacokinetic hypothesis, neural network hypothesis, intrinsic severity hypothesis, gene variant hypothesis, target hypothesis, and transporter hypothesis.
Conclusion
Despite the introduction of newer generations of ASDs, pharmacoresistance remains one of the biggest challenges in epilepsy treatment. In this review article, we summarize various theories that have been proposed to explain the mechanism(s) underlying refractory epilepsy with an emphasis on the transporter hypothesis.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
